Banco Santander, S.A. Press Releases

SAN 
$8.9
*  
0.02
0.23%
Get SAN Alerts
*Delayed - data as of Nov. 28, 2014  -  Find a broker to begin trading SAN now
Exchange: NYSE

Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
European CHMP Adopts Positive Opinion for Genzyme’s Cerdelga® (eliglustat) Capsules
11/21/2014 7:15:00 AM - Business Wire


Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis
11/20/2014 1:30:00 AM - PR Newswire


Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol
11/19/2014 8:15:00 AM - PR Newswire


Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol
11/19/2014 8:15:00 AM - PR Newswire


Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association
11/18/2014 3:45:00 PM - Business Wire


Sanofi Names Chief Scientific Officer Gary Nabel as Sanofi Ebola Response Coordinator
11/18/2014 11:22:00 AM - PR Newswire


Genzyme’s Lemtrada Approved by the FDA
11/14/2014 9:00:00 PM - Business Wire


Sanofi : Genzyme's Lemtrada Approved by the FDA
11/14/2014 8:58:00 PM - GlobeNewswire


Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
11/11/2014 1:00:00 AM - PR Newswire


Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
11/11/2014 1:00:00 AM - PR Newswire


Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis
11/4/2014 6:00:00 AM - Business Wire


Sanofi Pasteur Announces FDA Approval of Updated Prescribing Information for Fluzone® High-Dose Vaccine for Adults 65 and Older
11/3/2014 8:30:00 AM - PR Newswire


Banco Santander announces the outcome of the exchange offers in connection with Santander Brasil
10/31/2014 7:00:00 AM - PR Newswire


Statement from Sanofi Board of Directors
10/29/2014 3:58:00 AM - GlobeNewswire


Sanofi: Sanofi Delivers Business EPS Growth of 10.3% at CER
10/28/2014 8:34:00 AM - PR Newswire


New International GPCR Consortium Formed with Pharma and Academia to Advance Structural Information about G-protein Coupled Receptors
10/28/2014 6:00:00 AM - PR Newswire


Sanofi Q3 2014 Results - Interview with Jérôme Contamine
10/28/2014 3:00:00 AM - PR Newswire


Sanofi delivers Business EPS(1) growth of 10.3% at CER in Q3 2014
10/28/2014 2:45:00 AM - GlobeNewswire


Santander Holdings USA Declares Quarterly Dividend On Preferred Stock
10/22/2014 10:54:00 AM - PR Newswire
▲1.48 % Price Change since this news event. The Volume Ratio is 0.92.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio
10/20/2014 10:35:00 AM - Business Wire


US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine
10/20/2014 8:00:00 AM - Business Wire


Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis
10/20/2014 7:00:00 AM - PR Newswire


Sanofi Pasteur and Immune Design Enter Broad Collaboration for the Development of a Herpes Simplex Virus Therapy
10/16/2014 8:00:00 AM - GlobeNewswire


New Survey Finds Differences In Attitudes About Diabetes Based On Age
10/15/2014 8:00:00 AM - PR Newswire


Santander Sponsors Special Exhibition of Spanish Master Francisco Goya at Museum of Fine Arts, Boston
10/2/2014 12:02:00 PM - PR Newswire